DUBLIN, Dec. 11, 2014 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/d2tzcs/china_human) has announced the addition of the "China Human Vaccine Industry Report, 2014-2017" report to their offering.
Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China's human vaccine lot release volume grew by 4.9% from a year earlier, and the market size expanded 2.8% year on year. As vaccination is suspected of causing death and some companies (such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) have to shut down the production of some products after failing to pass the new GMP certification, China's human vaccine market supply and demand may witness a slight decline in 2014, but it is still expected to grow steadily in the long run.
Affected by China's economic level, national vaccine prevention policies and people's awareness, free EPI vaccines prevail in China with a share of approximately 80% in the total lot release volume. Also, the Chinese health authorities are trying to improve the quality of EPI vaccines. For example, Huizhou City of Guangdong province takes the lead to contain poliomyelitis inactivated vaccines into its immunization program (Sanofi Pasteur acts as a supplier in this program) for a trial in 2014. However, this program stipulates the injection of the poliomyelitis inactivated vaccine IPV for the first two vaccinations, while requires the oral administration of the poliomyelitis attenuated vaccine OPV for the third and fourth vaccinations.
Chinese human vaccine market is still dominated by Beijing Tiantan Biological, Chengdu Institute of Biology under Chinese Academy of Sciences, Shanghai Institute of Biological Products Co., Ltd. , Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd., Institute of Medical Biology under Chinese Academy of Medical Sciences and other state-owned enterprises; but, their market share is falling. In 2013, the lot release volume of Chinese state-owned enterprises accounted for 69.9%, down 8.6 percentage points compared with last year; whereas, the share of private and foreign-funded enterprises jumped by 6 percentage points and 2.6 percentage points over the previous year respectively.
The improved quality of Chinese vaccines, the increased export tax rebates (from 13% in 2009 to 15%) and other favorable factors have prompted China's human vaccine export volume and value to grow quickly. From January to June of 2014, the export volume and value amounted to 65.08 tons and USD15.45 million respectively, representing the separate increase of 115.6% and 50% over the same period of last year.
Key Topics Covered:
1. Overview of Vaccine Industry
2. China Human Vaccine Industry & Market
3. Human Vaccine Market Segments in China
4. China's Import and Export of Vaccines
5. Major Vaccine Manufacturers in China
- Beijing Tiantan Biological Products Co., Ltd
- Changchun BCHT Biotechnology Co. Ltd.
- Changchun Changsheng Life Sciences Limited
- China National Biotec Group
- Chongqing Zhifei Biological Products Co., Ltd
- Dalian Hissen Bio-Pharm Co., Ltd
- Hualan Biological Engineering Inc.
- Liaoning Chengda Co., Ltd.
- Shenzhen Kangtai Biological Products Co. Ltd
- Sinovac Biotech Ltd.
- Walvax Biotechnology Co., Ltd
- Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd
For more information visit http://www.researchandmarkets.com/research/d2tzcs/china_human
Media Contact: Laura Wood , +353-1-481-1716, email@example.com
SOURCE Research and Markets